BLC

Photocure ASA: Results for the fourth quarter of 2023

Retrieved on: 
Wednesday, February 21, 2024

Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®.

Key Points: 
  • Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®.
  • "Hexvix/Cysview revenue increased 20% year-over-year in the fourth quarter, and we delivered EBITDA of NOK 29.9 million.
  • Photocure reported total group revenues of NOK 142.5 million in the fourth quarter of 2023 (NOK 104.2 million), and EBITDA* of NOK 29.9 million (NOK -16.9 million), driven by a combination of unit volume growth, price increases and a benefit from foreign exchange.
  • At the end of the fourth quarter of 2023, the installed base of rigid blue light cystoscopy (BLC®) systems in the U.S. was 352, an increase of 17% or 51 towers since the fourth quarter of 2022.

Photocure ASA: Results for the fourth quarter of 2023

Retrieved on: 
Wednesday, February 21, 2024

Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®.

Key Points: 
  • Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®.
  • "Hexvix/Cysview revenue increased 20% year-over-year in the fourth quarter, and we delivered EBITDA of NOK 29.9 million.
  • Photocure reported total group revenues of NOK 142.5 million in the fourth quarter of 2023 (NOK 104.2 million), and EBITDA* of NOK 29.9 million (NOK -16.9 million), driven by a combination of unit volume growth, price increases and a benefit from foreign exchange.
  • At the end of the fourth quarter of 2023, the installed base of rigid blue light cystoscopy (BLC®) systems in the U.S. was 352, an increase of 17% or 51 towers since the fourth quarter of 2022.

Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, a Bladder Cancer Diagnosis and Management Drug, at the 2024 ASCO-GU

Retrieved on: 
Monday, January 29, 2024

The study included 158 patients enrolled in a randomized controlled trial (RCT), with 37 patients in the training group and 6 patients randomly assigned to the non-Blue Light Cystoscopy (BLC) group, one patient withdrew.

Key Points: 
  • The study included 158 patients enrolled in a randomized controlled trial (RCT), with 37 patients in the training group and 6 patients randomly assigned to the non-Blue Light Cystoscopy (BLC) group, one patient withdrew.
  • A total of 114 patients were in the full analysis set.
  • Nineteen patients were included in the real-world study (RWS).
  • The new drug application (NDA) for APL-1706 was accepted by the National Medical Products Administration (NMPA) in November 2023.

ProHance Announces Investment from Chrys Capital

Retrieved on: 
Thursday, December 7, 2023

Bangalore, India November 30, 2023: ProHance , a new-age workplace analytics and operations management platform company announced today a majority investment from ChrysCapital.

Key Points: 
  • Bangalore, India November 30, 2023: ProHance , a new-age workplace analytics and operations management platform company announced today a majority investment from ChrysCapital.
  • The investment will be primarily used to accelerate ProHance’s expansion across the globe and further strengthen its market dominance.
  • ProHance was founded by Kishore Reddy and Rajesh Sharma in 2009 with a vision of creating a world class global product out of India.
  • The investment marks ChrysCapital’s foray into the growing Indian SaaS ecosystem valued at over $12 billion.

Exploring $BLC: The Revolutionary Token Powering the Sastanaqqam Ecosystem

Retrieved on: 
Thursday, November 23, 2023

The $BLC token in the Sastanaqqam ecosystem serves several key utilities:

Key Points: 
  • The $BLC token in the Sastanaqqam ecosystem serves several key utilities:
    1.
  • The Sastanaqqam project ecosystem encompasses a variety of components that integrate decentralization, digitization, and entertainment within a Web 3.0 framework.
  • The key components of the ecosystem include:
    The heart of the ecosystem lies in its DeFi platforms, currently at 25% completion.
  • Overall, the Sastanaqqam ecosystem is a comprehensive blend of finance, art, entertainment, and education, all underpinned by blockchain technology and the use of its native $BLC token.

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

Retrieved on: 
Wednesday, November 29, 2023

OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.

Key Points: 
  • OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.
  • Hexvix, a pharmaceutical product used in the detection of bladder cancer, was licensed to Asieris by Photocure in January 2021, for the registration and commercialization of Hexvix in mainland China and Taiwan.
  • Moreover, Asieris' Phase III Hexvix trial is the first RCT that was conducted with high definition 4K blue light capital equipment.
  • The acceptance of the Hexvix submission by NMPA is the positive outcome of months of collaboration between the Asieris and Photocure teams," said Dan Schneider, President and CEO of Photocure.

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

Retrieved on: 
Wednesday, November 29, 2023

OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.

Key Points: 
  • OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China.
  • Hexvix, a pharmaceutical product used in the detection of bladder cancer, was licensed to Asieris by Photocure in January 2021, for the registration and commercialization of Hexvix in mainland China and Taiwan.
  • Moreover, Asieris' Phase III Hexvix trial is the first RCT that was conducted with high definition 4K blue light capital equipment.
  • The acceptance of the Hexvix submission by NMPA is the positive outcome of months of collaboration between the Asieris and Photocure teams," said Dan Schneider, President and CEO of Photocure.

Photocure ASA: Results for the third quarter of 2023

Retrieved on: 
Wednesday, November 8, 2023

OSLO, Norway, Nov. 8, 2023 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 (Q3 2022: NOK 96.9 million), and an EBITDA of NOK 3.3 million (NOK 4.7 million) for the company.

Key Points: 
  • OSLO, Norway, Nov. 8, 2023 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 (Q3 2022: NOK 96.9 million), and an EBITDA of NOK 3.3 million (NOK 4.7 million) for the company.
  • "In the third quarter, Hexvix/Cysview revenue increased 11% year-over-year and we delivered NOK 3.3 million in EBITDA while progressing numerous initiatives to advance our business.
  • The Hexvix®/Cysview® revenues ended at NOK 107.3 million in the quarter (Q3 2022: NOK 96.9 million).
  • At the end of the third quarter of 2023, the installed base of rigid blue light cystoscopy (BLC®) systems in the U.S. was 342, an increase of 23%, or 65 towers, since the third quarter of 2022.

Photocure ASA: Results for the third quarter of 2023

Retrieved on: 
Wednesday, November 8, 2023

OSLO, Norway, Nov. 8, 2023 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 (Q3 2022: NOK 96.9 million), and an EBITDA of NOK 3.3 million (NOK 4.7 million) for the company.

Key Points: 
  • OSLO, Norway, Nov. 8, 2023 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023 (Q3 2022: NOK 96.9 million), and an EBITDA of NOK 3.3 million (NOK 4.7 million) for the company.
  • "In the third quarter, Hexvix/Cysview revenue increased 11% year-over-year and we delivered NOK 3.3 million in EBITDA while progressing numerous initiatives to advance our business.
  • The Hexvix®/Cysview® revenues ended at NOK 107.3 million in the quarter (Q3 2022: NOK 96.9 million).
  • At the end of the third quarter of 2023, the installed base of rigid blue light cystoscopy (BLC®) systems in the U.S. was 342, an increase of 23%, or 65 towers, since the third quarter of 2022.

CAFP Disappointed Governor Vetoes Bill that Would Address Health Priorities

Retrieved on: 
Monday, October 9, 2023

SACRAMENTO, Calif., Oct. 9, 2023 /PRNewswire/ -- Despite the support of 30+ patient advocacy, health care, and community-based organizations, the governor vetoed AB 85 (Weber), a critical step in ensuring health equity and optimal health outcomes for California patients. Authored by Assemblymember Akilah Weber, MD, sponsored by the California Academy of Family Physicians (CAFP), and co-sponsored by the California Primary Care Association (CPCA), California Black Health Network (CBHN), and Black Leadership Council (BLC), AB 85 would have expanded access to social determinants of health screenings and resources.

Key Points: 
  • "We are extremely disappointed that the Governor squandered this opportunity to make this smart investment to improve health outcomes, lower health system costs and address inequities.
  • Health plans and insurers are crucial in providing the infrastructure and resources to connect their enrollees to critical health supports.
  • This bill would have been a significant step towards improving health outcomes and closing the gap in health disparities.
  • "Social determinants of health are a cause of health care inequity resulting in worsening health outcomes and increasing health care costs.